Table 1.

Baseline characteristics and demographics.

	All patients (N = 123)
Median age, years (range)	43.0 (22.0–76.0)
Female, n (%)	62 (50.4)
Median time since diagnosis, months (range)*	51.7 (1.0–405.7)
Mean mGH, μg/L (SD)†	10.2 (22.2)
Screening mGH stratum, n (%)
1.0–2.5 μg/L	28 (22.8)
>2.5 μg/L	94 (76.4)
Missing	1 (0.8)
Mean IGF-I, x ULN (SD)†	2.7 (1.2)
Diabetic status, n (%)‡
Diabetic	52 (42.3)
Pre-diabetic	60 (48.8)
Non-diabetic	11 (8.9)
Treatment prior to enrollment, n (%)
Lanreotide 120 mg	41 (33.3)
Octreotide 30 mg	29 (23.6)
Octreotide 40 mg	53 (43.1)

^*Three patients were enrolled and received pasireotide, who had been treated with octreotide or lanreotide for <3 months, noted as protocol deviations;

^†One patient had missing mGH and IGF-I values at baseline;

^‡Classification of patients as diabetic, pre-diabetic, or non-diabetic was performed according to multiple criteria as stated in the Methods. n, number of patients; SD, standard deviation.